ERYC 125 Drug Patent Profile
✉ Email this page to a colleague
When do Eryc 125 patents expire, and what generic alternatives are available?
Eryc 125 is a drug marketed by Parke Davis and is included in one NDA.
The generic ingredient in ERYC 125 is erythromycin. There are one hundred and three drug master file entries for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the erythromycin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Eryc 125
A generic version of ERYC 125 was approved as erythromycin by TORRENT on July 6th, 2020.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ERYC 125?
- What are the global sales for ERYC 125?
- What is Average Wholesale Price for ERYC 125?
Summary for ERYC 125
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 103 |
| Patent Applications: | 5,330 |
| DailyMed Link: | ERYC 125 at DailyMed |
US Patents and Regulatory Information for ERYC 125
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Parke Davis | ERYC 125 | erythromycin | CAPSULE, DELAYED REL PELLETS;ORAL | 062648-001 | Oct 24, 1985 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
